<DOC>
	<DOCNO>NCT00231335</DOCNO>
	<brief_summary>A primary hypothesis explore , give pharmacodynamic profile hypothesize mechanisms associate schizophrenia , escitalopram , comparison placebo , effective add risperidone olanzapine treat group reduce severity resistant symptom , particularly exist subsyndromal anxiety depression .</brief_summary>
	<brief_title>Efficacy Safety Study Escitalopram Augmentation Treatment Resistant Schizophrenia</brief_title>
	<detailed_description>The objective trial determine efficacy safety augment risperidone olanzapine escitalopram treatment symptom schizophrenia patient incomplete response adequate trial either two antipsychotic medication . To knowledge , first double blind randomize study design examine potential augmentation benefit escitalopram combine commonly used atypical agent chronic schizophrenic patient incomplete response risperidone olanzapine . The current proposal offer possibility test efficacy augmentation treatment control fashion clinical biological variable use indicator response tolerability . From broad perspective , would test hypothesis potential validity SSRI augmentation strategy treatment resistant symptom schizophrenia .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>1 . Meet DSM IV criterion schizophrenia adn schizoaffective disorder clinically stable fix dose risperidone olanzapine least 6 week . 2 . Incomplete response risperidone olanzapine least 6 week per subjective report minimum score rating instrument ( PANSS total &gt; 50 baseline ) . 3 . Current positive negative symptom sufficiently severe require adjuvant treatment despite good compliance adequate dos antipsychotic trial ( risperidone 4 6mg/day , olanzapine15 20mg/day 46 week treatment ) . 4 . Males females 1855 year age . No restriction recruitment base race . 5 . Able participate fully informed consent process legal guardian able participate inform consent process . All prospective research subject screen decisional capacity use MacArthur Competence Assessment ToolResearch ( MacCATCR ) 6 . Educational level least 10th grade . 7 . Score least PANSS psychosis item ( P1 , P2 , P3 , P5 , P6 ) &gt; 4 adn CGI Severity score &gt; 4 point maximum severity illness date total PANSS score baseline assess moderate ( PANSS total &gt; 50 ) . 1 . Meets full DSMIV criterion current Major Depressive Disorder , Bipolar Disorder , Anxiety Disorder active disorder Axis I . Present past history substance abuse exclusion criterion . 2 . Extrapyramidal symptom define score 4 SimpsonAngus rating scale . 3 . NonEnglish speaking . 4 . Serious unstable medical illness acute medical condition . 5 . Known allergy study medication . 6 . Serious suicidal homicidal risk . 7 . Participation clinical trial investigational drug within 30 day visit 1 . 8 . Evidence screen medical condition include limited : infection , electrolyte abnormality , recent physical trauma , malignancy , autoimmune disorder , endocrine disease neurological disease , history CNS trauma active seizure disorder require medication know history mental retardation . 9 . Any condition , opinion investigator would make patient unsuitable enrollment , could interfere participate complete protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>depression</keyword>
	<keyword>anxiety</keyword>
	<keyword>negative symptom</keyword>
</DOC>